ReviewVisceral medicine2016
Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.
Review in Visceral medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 50 citations in OpenAlex.
- Effects of short-term supervised exercise training on liver fat in adolescents with obesity: a randomized controlled trial.Obesity (Silver Spring, Md.) · 2023Trial
- Association Between Hepatic Steatosis and Deterioration of Metabolic Health in Obese Individuals: A 12-Year Follow-Up of the Tehran Lipid and Glucose Study.Endocrinology, diabetes & metabolism · 2026Article
- Association of Diet Quality, Dietary Acid Load, and Dietary Antioxidant Index With Cardiometabolic and NAFLD Risk Factors Among Patients With Metabolic Syndrome: A Cross-Sectional Study.Food science & nutrition · 2025Article
- Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.Journal of clinical medicine · 2025Review
- Review
- Epidemiology of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- Effectiveness of bariatric surgery on body mass, biochemical parameters, and steatosis in metabolically healthy vs. unhealthy obesity.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Biomarkers and Seaweed-Based Nutritional Interventions in Metabolic Syndrome: A Comprehensive Review.Marine drugs · 2024Review
- Association of liver fibrosis scores with all-cause and cardiovascular mortality in patients with heart failure.Clinical and translational science · 2024Article
- Ultrasound Versus Elastography in the Diagnosis of Hepatic Steatosis: Evaluation of Traditional Machine Learning Versus Deep Learning.Sensors (Basel, Switzerland) · 2024Article
- Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel, Switzerland) · 2024Review
- Comparison of the effects of monounsaturated fatty acids and polyunsaturated fatty acids on the lipotoxicity of islets.Frontiers in endocrinology · 2024Article
- Unraveling the Connection between Fatty Liver Severity with Gender, Lifestyle, and Health Risks among Workers.Nutrients · 2023Article
- Comparison of the Effects of Monounsaturated Fatty Acids and Polyunsaturated Fatty Acids on Liver Lipid Disorders in Obese Mice.Nutrients · 2023Article
- The Prospect of Non-Alcoholic Fatty Liver Disease in Adult Patients with Metabolic Syndrome: A Systematic Review.Cureus · 2023Review
- The Link between NAFLD and Metabolic Syndrome.Diagnostics (Basel, Switzerland) · 2023Review
- The association of hepatic steatosis and fibrosis with heart failure and mortality.Cardiovascular diabetology · 2021Article
- Article
- Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study.Obesity facts · 2021Article
- Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus.Journal of diabetes research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease throughout the world. Pathophysiological insights into this disease have recently illustrated that various factors such as insulin resistance, innate immunity, metabolic inflammation, and the microbiota are of relevance. NAFLD, metabolic syndrome (MS), and type 2 diabetes (T2D) share many pathophysiological aspects, and inflammatory processes in the adipose tissue, gut, and liver have evolved to be of exceptional importance. Most of NAFLD patients are obese and encounter a high risk of developing MS and T2D. NAFLD, however, is also highly common in subjects with MS and T2D. Furthermore, reflecting its nature of a multisystem disease, NAFLD is associated with a high prevalence and incidence of cardiovascular and chronic kidney disease. These facts require screening strategies for MS/T2D in NAFLD patients and vice versa. Thus, the question of cause or effect cannot be answered as MS and NAFLD share many pathomechanisms, and at the time of either diagnosis both frequently coexist. This is also reflected by a global prevalence rate of 25% for both NAFLD and MS. For this reason, it is crucial that physicians are aware of the 'unholy liaison' between MS, T2D, and NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.